**Specifications Table**TableSubject area*Biology*More specific subject area*Complement and Atherosclerosis*Type of data*Tables, Figure*How data was acquired*RNA-sequencing was performed using Illumina HiSeq 2500. Gene expression data were input into the DAVID online tool for Gene Ontology and KEGG Pathway analysis.*Data format*Analyzed, raw*Experimental factors*RNA was isolated from human monocyte-derived macrophages (HMDM) incubated with either oxidized (oxLDL) or acetylated low-density lipoprotein (acLDL) in the presence or absence of C1q.*Experimental features*RNA-seq analysis was performed and data subjected to gene ontology analysis to identify biological processes, molecular functions and cellular components modulated by C1q*Data source location*Long Beach, CA*Data accessibility*Analyzed data is within this article and raw data is available at the NCBI database at GEO series accession number GEO:*[GSE80442](ncbi-geo:GSE80442){#ir0015}*,*<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80442>

**Value of the data**•These data provide a list of all genes modulated in human macrophages during foam cell formation.•These data may be used to identify the effect of complement C1q opsonization on macrophage gene expression.•Gene ontology analysis identifies pathways that may provide therapeutic targets for restoring defective foam cell removal in atherosclerosis.

1. Data {#s0005}
=======

The data shown here include quantification of genes that were up or down-regulated by complement protein C1q in macrophages during ingestion of the atherogenic lipoproteins oxLDL and acLDL and gene ontology analysis. Overlapping upregulated and downregulated genes in the presence of C1q are visualized in Venn diagrams ([Fig. 1](#f0005){ref-type="fig"}). Data presented include gene ontology analysis based on biological processes of all significantly modulated genes ([Table 1](#t0005){ref-type="table"}), upregulated genes ([Table 2](#t0010){ref-type="table"}), and downregulated genes ([Table 3](#t0015){ref-type="table"}) due to C1q during ingestion of oxLDL or acLDL and the overlap of the genes in common between lipoprotein treatment. Gene ontology analysis of all modulated genes based on molecular function ([Table 4](#t0020){ref-type="table"}) and cellular component ([Table 5](#t0025){ref-type="table"}) are also provided. [Table 6](#t0030){ref-type="table"} includes KEGG pathway analysis of all C1q modulated genes based on canonical pathways.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design {#s0015}
------------------------

To examine and identify biological processes modulated by C1q during ingestion of modified lipoproteins in an unbiased manner, mRNA was collected from human monocyte-derived macrophages treated with physiologically relevant concentrations of oxidized and acetylated forms of LDL alone, or opsonized with C1q. RNA-seq was performed to identify genes that were up- or down-regulated by C1q in macrophages during ingestion of these atherogenic modified lipoproteins.

2.2. Cell isolation and lipoprotein treatment {#s0020}
---------------------------------------------

Human monocyte-derived macrophages (HMDM) were prepared from human blood of 10 donors, according to the guidelines and approval of California University Long Beach (CSULB) Institutional Review Board and as described [@bib2], [@bib3]. RNA was isolated from untreated HMDM or HMDM treated with 10 µg protein/ml oxLDL or acLDL alone, or opsonized with 75 µg/ml C1q. Cells were incubated at 37 °C for 3 h in 5% CO~2~ as described [@bib1].

2.3. RNA isolation and RNA-seq {#s0025}
------------------------------

RNA was isolated and RNA-seq was performed as described [@bib1].

2.4. Data analysis {#s0030}
------------------

Statistically significant differences in gene expression (*p*\<0.05) were determined using UCI׳s CyberT in-house software [@bib4]. The overlap of genes determined to be up- or down-regulated by C1q during acLDL or oxLDL treatment was shown with Venn diagrams ([Fig. 1](#f0005){ref-type="fig"}). Gene lists of all significantly modulated genes by C1q during ingestion of oxLDL or acLDL (*p*\<0.05) were used as input for gene ontology (GO) analysis ([Table 2](#t0010){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}) or KEGG pathway analysis ([Table 6](#t0030){ref-type="table"}) using DAVID ([https://david.ncifcrf.gov/](http://https://david.ncifcrf.gov/){#ir0025}) [@bib5]. In addition, resulting upregulated ([Table 2](#t0010){ref-type="table"}) and downregulated ([Table 3](#t0015){ref-type="table"}) gene lists were also used as input separately in DAVID. An adjusted EASE (Expression Analysis Systemic Explore Score) score of 0.05 and a threshold count of \>2 genes were used. Benjamini--Hochberg multiple testing correction was applied to the *p-*values. GO terms with FDR *q*\<0.05 were considered significantly enriched within the gene set. The overlap between oxLDL and acLDL gene sets for each GO term was also determined.
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![Overlap of genes modulated by C1q. HMDM pooled from 10 healthy donors were incubated with 10 µg protein/ml oxLDL or acLDL in the absence or presence of 75 µg/ml C1q for 3 h at 37 °C in triplicate. Differentially expressed genes from RNA-sequencing were determined using Cyber-T software (*n*=3, *p*\<0.05, *t*-test). Libraries were compared to each other to show the intersection of all significant genes upregulated, or downregulated by C1q between acLDL or oxLDL treatment.](gr1){#f0005}

###### 

Gene ontology analysis of all C1q modulated genes based on biological processes.

Table 1

  **Biological Processes GO Term: All Genes**       **Number of genes in the gene set**                                                   
  ------------------------------------------------- ------------------------------------------ ------------------------------------------ ----
  Immune response                                   105[⁎](#tbl1fnStar){ref-type="table-fn"}   98                                         39
  Defense response                                  87[⁎](#tbl1fnStar){ref-type="table-fn"}    88                                         38
  Inflammatory response                             56[⁎](#tbl1fnStar){ref-type="table-fn"}    55                                         23
  Response to wounding                              66[⁎](#tbl1fnStar){ref-type="table-fn"}    73                                         28
  Positive regulation of immune system process      37[⁎](#tbl1fnStar){ref-type="table-fn"}    37                                         15
  Positive regulation of cell activation            22[⁎](#tbl1fnStar){ref-type="table-fn"}    26                                         10
  Regulation of transcription                       --                                         324[⁎](#tbl1fnStar){ref-type="table-fn"}   --
  Anti-apoptosis                                    --                                         44[⁎](#tbl1fnStar){ref-type="table-fn"}    --
  RNA processing                                    53                                         88[⁎](#tbl1fnStar){ref-type="table-fn"}    26
  Programmed cell death                             --                                         95[⁎](#tbl1fnStar){ref-type="table-fn"}    --
  Cell death                                        62                                         108[⁎](#tbl1fnStar){ref-type="table-fn"}   37
  Death                                             62                                         108[⁎](#tbl1fnStar){ref-type="table-fn"}   37
  Apoptosis                                         --                                         93[⁎](#tbl1fnStar){ref-type="table-fn"}    --
  Transcription                                     --                                         261[⁎](#tbl1fnStar){ref-type="table-fn"}   --
  tRNA metabolic process                            17                                         28[⁎](#tbl1fnStar){ref-type="table-fn"}    7
  ncRNA metabolic process                           28                                         44[⁎](#tbl1fnStar){ref-type="table-fn"}    12
  I-kappaB kinase/NF-kappaB cascade                 10                                         19[⁎](#tbl1fnStar){ref-type="table-fn"}    7
  Positive regulation of protein kinase cascade     27                                         35[⁎](#tbl1fnStar){ref-type="table-fn"}    12
  Regulation of I-kappaB kinase/NF-kappaB cascade   19                                         26[⁎](#tbl1fnStar){ref-type="table-fn"}    9
  Regulation of programmed cell death               71                                         115[⁎](#tbl1fnStar){ref-type="table-fn"}   32

FDR *q*\<0.05.

###### 

Gene ontology analysis of all C1q upregulated genes based on biological processes.

Table 2

  **Biological processes GO term upregulated genes**               **Number of genes in the gene set**                                                  
  ---------------------------------------------------------------- ----------------------------------------- ------------------------------------------ ----
  Anti-apoptosis                                                   --                                        27[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Positive regulation of cellular biosynthetic process             31                                        54[⁎](#tbl2fnStar){ref-type="table-fn"}    21
  Regulation of transcription from RNA polymerase II promoter      27                                        56[⁎](#tbl2fnStar){ref-type="table-fn"}    18
  Positive regulation of biosynthetic process                      31                                        54[⁎](#tbl2fnStar){ref-type="table-fn"}    21
  Intracellular signaling cascade                                  52[⁎](#tbl2fnStar){ref-type="table-fn"}   81[⁎](#tbl2fnStar){ref-type="table-fn"}    31
  Positive regulation of nitrogen compound metabolic process       28                                        50[⁎](#tbl2fnStar){ref-type="table-fn"}    19
  Positive regulation of macromolecule biosynthetic process        28                                        50[⁎](#tbl2fnStar){ref-type="table-fn"}    20
  Apoptosis                                                        --                                        47[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Programmed cell death                                            --                                        47[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Cell death                                                       --                                        52[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Protein kinase cascade                                           18                                        33[⁎](#tbl2fnStar){ref-type="table-fn"}    13
  Regulation of transcription                                      --                                        138[⁎](#tbl2fnStar){ref-type="table-fn"}   --
  Positive regulation of transcription, DNA-dependent              22                                        39[⁎](#tbl2fnStar){ref-type="table-fn"}    15
  Death                                                            --                                        52[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Positive regulation of RNA metabolic process                     22                                        39[⁎](#tbl2fnStar){ref-type="table-fn"}    15
  Regulation of programmed cell death                              --                                        56[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Positive regulation of NF-kappaB transcription factor activity   --                                        10[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Regulation of cell death                                         --                                        56[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  I-kappaB kinase/NF-kappaB cascade                                --                                        12[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Regulation of apoptosis                                          --                                        55[⁎](#tbl2fnStar){ref-type="table-fn"}    --

FDR *q*\<0.05.

###### 

Gene ontology analysis of all C1q downregulated genes based on biological processes.

Table 3

  **Biological Processes GO Term Downregulated Genes**   **Number of genes in the gene set**                                                 
  ------------------------------------------------------ ----------------------------------------- ----------------------------------------- ----
  Immune response                                        79[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        --
  Defense response                                       59[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        --
  Inflammatory response                                  37[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        --
  Response to virus                                      17[⁎](#tbl3fnStar){ref-type="table-fn"}   15                                        --
  ncRNA metabolic process                                24                                        40[⁎](#tbl3fnStar){ref-type="table-fn"}   12
  tRNA metabolic process                                 14                                        26[⁎](#tbl3fnStar){ref-type="table-fn"}   7
  RNA processing                                         39                                        67[⁎](#tbl3fnStar){ref-type="table-fn"}   19
  DNA repair                                             --                                        42[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  ncRNA processing                                       19                                        30[⁎](#tbl3fnStar){ref-type="table-fn"}   10
  Response to DNA damage stimulus                        --                                        47[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  DNA metabolic process                                  --                                        57[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Translation                                            26                                        41[⁎](#tbl3fnStar){ref-type="table-fn"}   12

FDR *q*\<0.05.

###### 

Gene ontology analysis of all C1q modulated genes based on molecular function.

Table 4

  **Molecular function GO term all genes**   **Number of genes in the gene set**                                              
  ------------------------------------------ ------------------------------------- ------------------------------------------ ----
  RNA binding                                72                                    110[⁎](#tbl4fnStar){ref-type="table-fn"}   41
  Zinc ion binding                           --                                    285[⁎](#tbl4fnStar){ref-type="table-fn"}   
  Transition metal ion binding               --                                    329[⁎](#tbl4fnStar){ref-type="table-fn"}   
  DNA binding                                --                                    281[⁎](#tbl4fnStar){ref-type="table-fn"}   

FDR *q*\<0.05.

###### 

Gene ontology analysis of all C1q modulated genes based on cellular component.

Table 5

  **Cellular component GO term: All genes**      **Number of genes in the gene set**                                              
  ---------------------------------------------- ------------------------------------- ------------------------------------------ ----
  Intracellular organelle lumen                  145                                   255[⁎](#tbl5fnStar){ref-type="table-fn"}   75
  Membrane-enclosed lumen                        149                                   262[⁎](#tbl5fnStar){ref-type="table-fn"}   77
  Organelle lumen                                146                                   256[⁎](#tbl5fnStar){ref-type="table-fn"}   75
  Nuclear lumen                                  123                                   214[⁎](#tbl5fnStar){ref-type="table-fn"}   68
  Nucleolus                                      69                                    116[⁎](#tbl5fnStar){ref-type="table-fn"}   36
  Intracellular non-membrane-bounded organelle   --                                    304[⁎](#tbl5fnStar){ref-type="table-fn"}   
  Non-membrane-bounded organelle                 --                                    304[⁎](#tbl5fnStar){ref-type="table-fn"}   
  Ribonucleoprotein complex                      --                                    84[⁎](#tbl5fnStar){ref-type="table-fn"}    
  Nucleoplasm                                    --                                    123[⁎](#tbl5fnStar){ref-type="table-fn"}   
  Cytosol                                        111                                   166[⁎](#tbl5fnStar){ref-type="table-fn"}   49
  Miitochondrion                                 82                                    133[⁎](#tbl5fnStar){ref-type="table-fn"}   38

FDR *q*\<0.05.

###### 

KEGG analysis of all C1q modulated genes based on canonical pathways.

Table 6

  **KEGG Canonical Pathways: All Genes**   **Number of genes in the gene set**        
  ---------------------------------------- ------------------------------------- ---- ----
  Toll-like receptor signaling pathway     16                                    23   7
  Apoptosis                                14                                    20   8
  RIG-I-like receptor signaling pathway    --                                    17   --
  Ubiquitin mediated proteolysis           --                                    26   --
  Pyrimidine metabolism                    --                                    19   --
  NOD-like receptor signaling pathway      11                                    14   6
  Acute myeloid leukemia                   --                                    13   --
  Neurotrophin signaling pathway           --                                    21   --
  B cell receptor signaling pathway        --                                    14   --
  Arginine and proline metabolism          --                                    11   --
  Small cell lung cancer                   --                                    15   --
  Aminoacyl-tRNA biosynthesis              --                                    9    --
  Cytokine-cytokine receptor interaction   38                                    --   --
  Systemic lupus erythematosus             17                                    --   --
  Jak-STAT signaling pathway               21                                    --   --
  RIG-I-like receptor signaling pathway    12                                    --   --
  Chemokine signaling pathway              23                                    --   --
